Bank Of New York Mellon Corp Sigilon Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.74 - $1.64 $32,830 - $72,760	-44,366 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$1.24 - $3.03 $8,990 - $21,967	-7,250 Reduced 14.05%	44,366 $66,000
Q4 2021 Feb 11, 2022	BUY	$2.58 - $6.13 $31,107 - $73,909	12,057 Added 30.48%	51,616 $142,000
Q3 2021 Nov 12, 2021	BUY	$4.42 - $10.61 $55,303 - $132,752	12,512 Added 46.26%	39,559 $223,000
Q2 2021 Aug 11, 2021	BUY	$9.15 - $20.17 $89,358 - $196,980	9,766 Added 56.51%	27,047 $290,000
Q1 2021 May 13, 2021	BUY	$18.76 - $40.91 $324,191 - $706,965	17,281 New	17,281 $386,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.